Key Highlights

  • Net loss narrowed to USD 1.4 million from USD 9.9 million.
  • Loss per share was USD 0.26, against USD 4.41 a year earlier.
  • Cash and cash equivalents stood at USD 18.7 million.
  • No Research and Development expense was incurred in the quarter.

Neuphoria Therapeutics (NASDAQ:NEUP) is now a company waiting on a deal. On July 23, 2026 it entered a Merger agreement with Scancell Holdings plc, under which each common share would convert into American Depositary Shares of the successor parent at an agreed exchange ratio, plus one contingent value right. The company says its main activities are to complete the merger, preserve cash, meet public-company and contractual duties and manage interests in partnered programs.

The third-quarter net loss was USD 1,425,104 versus USD 9,906,504, or USD 0.26 per share versus USD 4.41. The estimated loss was USD 1.58 per share. The operating loss was USD 2,095,375 versus USD 5,652,689. No research and development expense was incurred, because the company discontinued development of BNC210 for social anxiety disorder and halted its internal preclinical programs.

General and administrative expense rose 12.2% to USD 2,095,375 from USD 1,867,040, which the company attributed to USD 0.5 million of higher professional services costs, partly offset by lower headcount costs.

Other Income and Cash

Other income was USD 635,478 versus an other loss of USD 4,288,608, a swing of USD 4.9 million driven by Fair Value adjustments on a Warrant Liability and a contingent consideration liability. The gain on fair value adjustments was USD 790,884 versus a loss of USD 4,368,869. Loss before income taxes was USD 1,459,897 versus USD 9,941,297, and the income tax benefit was USD 34,793 in both periods.

Net cash used in Operating Activities was about USD 1.1 million versus USD 3.8 million. Financing provided less cash, since the prior-year quarter included about USD 3.3 million from an at-the-market facility. Cash and cash equivalents were USD 18,744,060 versus USD 19,865,531 at the prior year-end. Interest income was USD 169,117 versus USD 141,996, and the foreign currency transaction loss was USD 192,515 versus USD 61,735.

Balance Sheet and Partnered Programs

Total Assets were USD 27,105,149, with current assets of USD 19,600,963. Total liabilities were USD 3,634,964 versus USD 4,108,994, and Accounts Payable rose to USD 724,696 from USD 385,584. The warrant liability was USD 1,705,435 versus USD 1,971,172, and contingent consideration was USD 522,523 versus USD 1,025,301. Shareholders' Equity was USD 23,470,185 against an accumulated Deficit of USD 193,223,738, with 5,411,334 shares outstanding. Unrealized foreign currency translation gains were USD 220,549 versus USD 49,221.

Goodwill was USD 3,527,809 at September 30, after a Goodwill Impairment charge of about USD 5.4 million at June 30, 2026 tied to lower expected cash flows from potential MK-1167 commercialization. Management saw no further impairment indicators at quarter end. Partnered programs include a BNC101 license to Carina Biotech and a Merck agreement covering MK-1167, whose Phase 2 trial was terminated.

Merger conditions and timing, general and administrative cost levels, the cash balance and developments in the partnered programs are the points to follow.